Cytosorb filter: An adjunct for survival in the COVID-19 patient in cytokine storm? a case report #MMPMID33041058
Rizvi S; Danic M; Silver M; LaBond V
Heart Lung 2021[Jan]; 50 (1): 44-50 PMID33041058show ga
COVID-19 is a pandemic that has affected not only the United States, but the entire world. The impact it has had has overwhelmed the entire healthcare system, from the unknown carrier status, poor testing capabilities to hospitals running out of ventilators for severely ill patients. There has been a variety of potential treatment modalities for the various forms of illness ranging from asymptomatic carriers to the ventilated ICU patients. These include anti-inflammatory medications, antibiotics, immune-modulators, convalescent plasma, and others. The cytokine storm that inflicts some patients can be devastating to the vital organs of the human body in the form of acute respiratory distress syndrome (ARDS), renal failure, coagulopathy, and death. Cytosorbents(R) cytokine filter is a potential treatment methodology aimed at reducing the cytokine storm, thus serving as a bridge for therapy in the acutely ill patients infected with COVID-19. The following case report demonstrates the utility in a critically ill patient who survived the cytokine storm after receiving the cytokine filter via continuous renal replacement therapy bridging him to further definitive therapy.
free
free
free
Heart+Lung 2021 ; 50 (1): 44-50
